Document:

Non-Exclusive License Agreement

 Exhibit 10.29 
  
 Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information
subject to the confidentiality request. Omissions are designated as [*****]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 
  
 NON-EXCLUSIVE LICENSE AGREEMENT 
  
 This Agreement is entered into as of the 20th day of October, 1999 (“Effective Date”) by and between the Fred
Hutchinson Cancer Research Center, a Washington non-profit corporation (“FHCRC”) and Xcyte Therapies, Inc (“LICENSEE”), a Delaware corporation having a place of business at 2203 Airport Way S., Suite 300, Seattle, Washington
98134. All references to LICENSEE shall include its AFFILIATES. 
  
 RECITALS 
  
 A. FHCRC has developed and owns the valuable
[*]; 
  
 B. FHCRC is committed to a policy that ideas or
creative works produced at FHCRC should be used for the greatest possible public benefit and believes that every reasonable incentive should be provided for the prompt introduction of such ideas into public use, all in a manner consistent with the
public interest; 
  
 C. LICENSEE desires to obtain a worldwide
license in and to the above-referenced rights; and 
  
 D. FHCRC is
willing to grant such a license to LICENSEE subject to the terms and conditions of this Agreement. 
  
 TERMS AND CONDITIONS 
  
 The parties agree as follows: 
  
 ARTICLE 1 - DEFINITIONS 
  
 1.1 “AFFILIATE” shall mean
any corporation or other entity which is directly or indirectly controlling, controlled by or under the common control with a party hereto which has agreed in writing to be bound by the terms of this Agreement. For the purpose of this Agreement,
“control” shall mean the direct or indirect ownership of at least thirty percent (30%) of the outstanding shares or other voting rights of the subject entity to elect directors, or if not meeting the preceding, any entity owned or
controlled by or owning or controlling at the maximum control or ownership right permitted in the country where such entity exists. “Affiliates” includes only Affiliates of LICENSEE and does not include Affiliates of LICENSEE’s
Affiliates. 
  
 1.2 “LICENSED CELL LINE” means the [*]. Such
derivatives and modifications shall not include antibodies which are not derived from or developed using the Licensed Materials and which have been entirely made with the use of information or materials available in the public domain. 
  
 1.3 “LICENSED MONOCLONAL ANTIBODY” means the [*], produced by or derived
from the licensed CELL LINE. 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 1.4 “LICENSED PRODUCTS” means any product, including reagents, devices, kits and packages that contain, or are
derived from, or result from the use of the LICENSED MONOCLONAL ANTIBODY including without limitation beads coated with the LICENSED MONOCLONAL ANTIBODY either by itself or in combination with other antibodies. LICENSED PRODUCTS does not include the
LICENSED CELL LINE. 
  
 1.5 “LICENSED SERVICES” means any service
performed for a third party using a LICENSED PRODUCT or the LICENSED MONOCLONAL ANTIBODY. Services performed on biological materials from a single patient which are clinically defined to constitute a single course of treatment shall constitute the
performance of a single LICENSED SERVICE procedure for purposes of Section 5.2 of this Agreement. 
  
 1.6 “FIELD” means [*]. 
  
 1.7
“NET SALES” means the amount actually received by LICENSEE and its AFFILIATES or sublicensees on sales of LICENSED PRODUCTS and LICENSED SERVICES less: 
  
 (a) Customary trade, quantity or cash discounts and non-affiliated brokers’ or agents’ commissions actually
allowed and taken; 
  
 (b) Amounts repaid or credited by reason
of rejection or return; and/or 
  
 (c) To the extent separately
stated on purchase orders, invoices or other documents of sales, taxes levied on and/or other governmental charges made as to production, sale, transportation, delivery or use and paid by or on behalf of LICENSEE; and/or Import and I or export
duties actually paid. 
  
 (d) NET SALES shall include all
consideration received for a sale and shall be based on the usual full arms length third party price in the event that LICENSED PRODUCT is transferred at a lower sum. 
  
 ARTICLE 2 - GRANT 
  
 2.1 Non-Exclusive License. FHCRC hereby grants to LICENSEE and LICENSEE accepts subject to the terms and conditions hereof the following licenses: 
  
 (a) a non-exclusive license to use, possess, culture and employ the LICENSED
CELL LINE at its business premises solely in the United States; 
  
 (b) a worldwide, non-exclusive license to the LICENSED MONOCLONAL ANTIBODY to make and have made, to use, to sell, have sold and offer for sale the LICENSED PRODUCTS and the LICENSED SERVICES in the FIELD for the term of this Agreement
(collectively the “Licenses”). Notwithstanding any other provision of this Agreement, (1) LICENSEE and its Affiliates shall not use the LICENSED CELL LINE or LICENSED MONOCLONAL ANTIBODY for any purpose other than that expressly described
in this Agreement (2) shall not transfer the LICENSED CELL LINE to any third party or AFFILIATE for any purpose except to a sublicensee as provided in Section 

  

 2 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 
2.2(a) of this Agreement and (3) shall in no event transfer the LICENSED CELL LINE outside of the United States. 
  
 2.2 Sublicensing 
  
 (a) LICENSEE shall have no right or power to grant sublicenses of the LICENSED CELL LINE, under section 21. (a), except
LICENSEE shall have the right to sublicense third parties to make the LICENSED MONOCLONAL ANTIBODY on behalf of LICENSEE solely for the use of LICENSEE, its AFFILIATES and sublicensees subject to FHCRC’s prior written consent, which consent
shall not be unreasonably withheld. If FHCRC does not respond in thirty (30) days to written request for consent from LICENSEE, such non-response shall constitute consent by FHCRC hereunder. In addition to any other requirements imposed under this
Agreement, a sublicense of the LICENSED CELL LINE shall require that the LICENSED CELL LINE be maintained in and not transferred from the United States and will prohibit the sublicensee from sublicensing or otherwise transferring the LICENSED CELL
LINE to any other person or entity. Upon the prior written approval of FHCRC, which shall not be unreasonably withheld, LICENSEE may sublicense on third party to make the LICENSED MONOCLONAL ANTIBODY in Europe on behalf of LICENSEE solely for the
use of LICENSEE, its AFFILIATES and sublicensees upon terms and conditions agreeable to FHCRC. A determination by FHCRC that a sublicense will affect adversely its rights in the LICENSED CELL LINE or the LICENSED MONOCLONAL ANTIBODY or its ability
to enforce those rights shall be deemed a reasonable basis to withhold consent to that sublicense for purposes of this Section 2.2(a). 
  
 (b) LICENSEE may grant and authorize sublicenses to permit third parties to perform LICENSED SERVICES and to make, have made, use and sell LICENSED
PRODUCTS (but not the LICENSED CELL LINE) within the scope of the License described in Section 2.1(b) of this Agreement with FHCRC’s prior written consent, which consent will not be unreasonably withheld. If FHCRC does not respond in thirty
(30) days to written request for consent from LICENSEE, such non-response shall constitute consent by FHCRC hereunder. All sublicenses granted by LICENSEE under this Section 2.2 (b) shall include a requirement that the sublicensesee use reasonable
efforts to introduce the LICENSED PRODUCTS into the commercial market as soon as reasonably possible, consistent with sound and reasonable business practices and judgment, and thereafter endeavor to keep LICENSED PRODUCTS reasonably available to the
public. 
  
 (c) In addition to any other requirements of this
Agreement, any sublicense agreement under this Section 2.2 shall bind the sublicensee to meet all LICENSEE’s obligations to FHCRC under this Agreement. Royalties charged for sublicenses by LICENSEE shall be commercially reasonable. LICENSEE
shall promptly provide FHCRC with a copy of any sublicense agreement subject to the confidentiality provisions of Article 10 of this Agreement. 
  
 (d) Notwithstanding 2.2 (a)-(c), LICENSEE may transfer the LICENSED MONOCLONAL ANTIBODY to third parties, and if required by such third party, 

  

 3 

 
sublicense the LICENSED MONOCLONAL ANTIBODY for the purpose of testing, analysis, development or manufacturing of LICENSED PRODUCTS or LICENSED SERVICES to
be sold or offered for sale by LICENSEE or authorized sublicensees; provided that the third party to whom the transfer is made has agreed (1) in writing to use the LICENSED MONOCLONAL ANTIBODY solely for that limited purpose and has agreed (2) not
to make, use or sell or offer for sale or otherwise distribute or exploit the LICENSED MONOCLONAL ANTIBODY or any LICENSED PRODUCT or LICENSED SERVICE and (3) to be bound by the Confidentiality provisions in Article 10 of this Agreement. 

 
 2.3 Restrictions on License. Notwithstanding any other provision of this Agreement,
the License is subject to the following policies, obligations and/or conditions: 
  
 (a) FHCRC’s Patents and Inventions Policy adopted September 30, 1983, Public Laws 96-517 and 98-620 and FHCRC’s obligations under agreement with other sponsors of research. Any right granted in this
Agreement greater than that permitted under Public Laws 96-5 17 or 98-620 shall be subject to modification as may be required to conform to the provisions of the statutes. 
  
 (b) LICENSEE agrees during the term of the License that any LICENSED MONOCLONAL ANTIBODY produced for sale in the United
States will be manufactured substantially in the United States. 
  
 ARTICLE 3 - TERM OF AGREEMENT 
  
 3.1 Term. The term of
this Agreement commences on the Effective Date and, subject to earlier termination as provided in Article 9, shall remain in effect for fifteen (15) years following the first sale of a LICENSED PRODUCT or LICENSED SERVICE by LICENSEE to a customer
who is not an AFFILIATE or sublicensee (“First Commercial Sale”). Upon expiration of the term, provided LICENSEE is not in material breach of this Agreement, the licenses granted LICENSEE under this Agreement shall be deemed fully paid-up.

  
 ARTICLE 4 - DELIVERY OF LICENSED MATERIAL 
  
 4.1 Delivery of [*]. Within thirty (30) days of receipt by FHCRC of any Signing
Fee owed under this Agreement, the Effective Date, FHCRC shall provide to LICENSEE [*] from the Manufacturer’s Working Cell Bank (“MWCB”). 
  

4.2 Replacement of [*]. If the [*] dies during the Term of this Agreement, FHCRC will, after it has been reimbursed its reasonable costs and
expenses by LICENSEE, and no more than two occasions during the Term, provide to LICENSEE sufficient quantities of additional seed stock from the MWCB to replace the cell line, but in no event more then a total of two additional vials. 

 
 4.3 Antibody Production. The parties acknowledge that LICENSEE has contracted with
FHCRC for production and supply of the [*] pursuant to a Laboratory Services Agreement dated even herewith. 
  

 4 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 ARTICLE 5 - PAYMENTS 
  
 5.1 Signing Fee. LICENSEE shall pay to FHCRC a non-refundable signing fee in the sum of [*], which shall be due and payable
within five (5) days of the execution of this Agreement. 
  
 5.2 Earned
Royalties. LICENSEE shall pay to FHCRC a royalty in the amount of [*] of the NET SALES of all LICENSED PRODUCTS, and [*] of the NET SALES of all LICENSED SERVICES sold by LICENSEE during the Term. The royalty payable with respect
to the performance of a single LICENSED SERVICE procedure shall not exceed [*] (the “LICENSED SERVICES Royalty Cap”) for a period of [*]. Thereafter, the LICENSED SERVICES Royalty Cap shall increase at the rate of [*].
LICENSEE shall also pay FHCRC a) [*] and [*] received as a result of a sublicense of LICENSED SERVICES , b) and [*] received as a result of a sublicense of LICENSED PRODUCTS, all within thirty (30) days of receipt of such
consideration; provided, however, that to the extent the non-royalty consideration received as a result of a sublicense is paid to LICENSEE as funding for a specific research project, LICENSEE may at its option elect to give FHCRC a
negotiable promissory note in the principal amount of such funding payable in twenty-four (24) months from the date the funding is received by LICENSEE together with interest thereon at a per annum rate equal to the prime rate of Bank of America,
adjusted quarterly. Non-cash consideration received by LICENSEE on account of a sublicense shall be appraised at LICENSEE’s expense using a third party acceptable to FHCRC. Non-cash consideration includes, without limitation, debt, equity or
other financial instruments, real property, tangible personal property, rights and patents, patent applications, trade secrets and licenses to such patents, patent applications and trade secrets. Non-royalty sublicense income includes, without
limitation, signing fees, upfront fees, license issue fees, license maintenance fees, milestone payments or other payments paid as consideration for the right to sell or otherwise distribute LICENSED PRODUCTS or LICENSED SERVICES whether structured
as a sublicense, joint venture, collaboration or other arrangement. On sales between LICENSEE’S and its AFFILIATES or authorized sublicensees for resale royalties shall be paid on the resale. 
  
 5.3 Combined Products. In the event that any of the LICENSED PRODUCTS or LICENSED
SERVICES are used or sold by LICENSEE in combination as a single product or service with one or more other product(s) or service(s) whose sale and/or use are not within the scope of the this Agreement, and do not entail the use of the LICENSED
MONOCLONAL ANTIBODY, NET SALES from such sales and/or use for purposes of calculating the amounts due under Section 5.2 above shall be calculated by multiplying the NET SALES of that combination by the faction A/(A+B), where A is the gross selling
price of the LICENSED PRODUCT or LICENSED SERVICE sold separately and B is the gross selling price of the other product or service sold separately. In the event that no such separate sales or use are made by LICENSEE, NET SALES for purposes of
royalty determination shall be as reasonably allocated by LICENSEE between such LICENSED PRODUCT or LICENSED SERVICE and such other product or service, based upon their relative importance and proprietary protection. It is understood and agreed that
LICENSEE intends to use LICENSED PRODUCTS and LICENSED SERVICES in connection with products and services provided by LICENSEE which do not entail the use of the LICENSED MONOCLONAL ANTIBODY, and that such products and services shall be subject to
this Section 5.3. 
  

 5 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 5.4 One Royalty. No more than one royalty payment shall be due with respect to a sale of a particular LICENSED
PRODUCT. No royalty shall be payable under this Article 5 with respect to LICENSED PRODUCTS, distributed at no charge, for use in research and/or development, in clinical, in clinical trials or as promotional samples. When a LICENSED PRODUCT is
used, sold or sublicensed as part of LICENSED SERVICES, the royalty rate and other changes applicable to LICENSED SERVICES shall apply and no royalty or charge shall be made for the LICENSED PRODUCT in that case. 
  
 ARTICLE 6 - REPORTING AND ROYALTY PAYMENT TERMS 
  
 6.1 First Sales. LICENSEE shall report to FHCRC the date of first sale of LICENSED
PRODUCTS and or LICENSED SERVICES in each country within thirty (30) days of occurrence. 
  
 6.2 Sales Reports and Royalty Payments. Commencing upon the First Commercial Sale, LICENSEE shall submit to FHCRC within sixty (60) days after June 30 and December 31 of each year during the Term, and upon the
effective termination Of this Agreement, reports for the preceding six (6) month period identifying the amount of the LICENSED PRODUCTS or LICENSED SERVICES sold by LICENSEE, its AFFILIATES and sublicensees in each country, the sales volume and NET
SALES, and the amount of royalty due to FHCRC together with payment of such royalty amount. Such report shall be certified as correct by an officer of LICENSEE and shall include a detailed listing of all deductions from NET SALES, sublicensee income
or from royalties as specified herein. If no royalties are due to FHCRC for any reporting period, the written report shall so state. All payments due hereunder shall be paid in United States Dollars. If any currency conversion shall be required in
connection with the payment of any royalties hereunder, such conversion shall be made by using the exchange rate for the purchase of United States Dollars reported by the Bank of America on the last business day of the calendar quarter to which such
royalty payments relate. If at any time legal restrictions prevent the prompt remittance of any royalties owed on NET SALES in any jurisdiction, LICENSEE shall notify FHCRC and make such payments by depositing the amount thereof in local currency in
a bank account or other depository in such country in the name of FHCRC. All payments shall be without deduction of exchange, collection or other charges. Without regard to or waiver of any other remedies that may be available under this Agreement,
any royalty payments not made when due shall bear interest at the rate of [*] per annum, compounded daily. 
  
 6.3 Withholding Taxes on Royalties. To the extent that any earned royalties due FHCRC under this Agreement are subject to taxation where the taxes are imposed on
FHCRC, FHCRC agrees to bear such taxes. FHCRC hereby authorizes LICENSEE or sublicensee to withhold such taxes from the payment which are otherwise payable to FHCRC in accordance with this Agreement if LICENSEE or sublicensee is either required to
do so under the tax laws of the country of sale or in the United States or directed to do so by an agency of either such government. LICENSEE shall furnish FHCRC with relevant documentation showing assessment of the taxes and the best available
evidence of payment whenever LICENSEE or sublicensee deducts such tax from any payments due FHCRC. 
  
  

 6 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 6.4 Confidentiality of Reports. All such reports shall be maintained in confidence by FHCRC, except as required by
law, including Public Laws 96-517 and 98-620. 
  
 ARTICLE 7 -
RECORD KEEPING 
  
 7.1 Recordkeeping. LICENSEE shall maintain and
require each sublicensee to maintain complete and accurate books of account and records showing all sales of LICENSED PRODUCTS and all NET SALES (including the amount of gross sales and allowable deductions attributable to such sales). For purposes
of verifying the accuracy of the royalties paid by LICENSEE pursuant to this Agreement or verifying performance of LICENSEE of any other obligation to FHCRC hereunder, such books and records shall be open to inspection and copying, during usual
business hours, by an independent certified public accountant. Such accountant shall not disclose to FHCRC any information other than information relating to accuracy of reports and calculations of amounts due to FHCRC made under this Agreement. In
the event that any such inspection shows any underreporting and underpayment by LICENSEE in excess of five percent (5%) for any twelve (12) month period, then LICENSEE shall pay the cost of such examination. Such books and records shall be
maintained for at least three (3) years following the reporting period to which the books and records relate. 
  
 ARTICLE 8 - INDEMNIFICATION AND INSURANCE 
  
 8.1 Indemnification. LICENSEE, including any successor to LICENSEE, shall, and shall obligate its AFFILIATES or its sublicensees, if any, to indemnify, defend and hold harmless FHCRC, its AFFILIATES and their
respective directors, officers, employees, agents and contractors (each an “Indemnitee”) from and against any and all liabilities, damages, losses, costs or expenses (including reasonable attorneys’ and professionals’ fees and
other expenses of litigation and/or arbitration (a “Liability”)) resulting from a claim, suit or proceeding brought against an Indenmitee, arising out of or in connection with or resulting from (i) any misrepresentation with regard to, or
breach of, any of the representations and warranties of LICENSEE set forth in Section 12 of this Agreement, (ii) the use, development, manufacture, distribution, sublicensing or sale of the LICENSED PRODUCTS or LICENSED SERVICES by LICENSEE or its
AFFILIATES or sublicensees except to the extent caused by the negligence or willful misconduct of FHCRC, including without limitation any Liabilities resulting from infringement of third party intellectual property rights, and (iii) any other
activities performed by LICENSEE or its AFFILIATES or sublicensees pursuant to this Agreement. 
  
 8.2 FHCRC. FHCRC shall indemnify, defend and hold harmless LICENSEE and its directors, officers and employees (each an “Indemnitee”) from and against any and all liabilities, damages, losses, costs or
expenses (including reasonable attorneys’ and professionals’ fees and other expenses of litigation and/or arbitration) resulting from a claim, suit or proceeding brought against an Indemnitee, arising out of or in connection with any
misrepresentation with regard to, or breach of, any of the representations and warranties of FHCRC set forth in Section 12, except to the extent caused by the negligence or willful misconduct of LICENSEE. 
  
 8.3 Insurance. In the event of any testing or use in human subjects of LICENSED
PRODUCTS, LICENSEE will have FHCRC named as an additional insured on LICENSEE’S 

  

 7 

 
product liability insurance policies, with limits of at least [*]. Upon the First Commercial Sale, LICENSEE will have FHCRC named as an additional
insured on LICENSEE’s product liability insurance policies, with limits of [*]. Such policies shall not be terminated without thirty (30) days prior written notice to FHCRC. LICENSEE shall provide FHCRC with written evidence of the
insurance and a copy of the policy upon request. 
  
 8.4 Legal Action. In
the event any legal action is commenced against LICENSEE involving the LICENSED MONOCLONAL ANTIBODY, LICENSED CELL LINE, LICENSED PRODUCTS and/or LICENSED SERVICES, whether or not FHCRC is named as a party to the legal action, LICENSEE shall keep
FHCRC or its attorney nominee fully advised of the progress of the legal action and shall reimburse FHCRC for its reasonable legal costs (including attorney’s fees) incurred as a result of FHCRC’s employees or agents being called as
witnesses therein or asked to testify for or consult with LICENSEE in connection therewith. FHCRC agrees to cooperate with LICENSEE, to the extent reasonably possible, in any legal action brought pursuant to this Article 8. 
  
 ARTICLE 9 - DISPUTE RESOLUTION 
  
 9.1 The parties do not favor litigation. Therefore, unless a party is entitled to injunctive
relief, as ultimately determined by a court of competent jurisdiction, because (i) the party is exposed to irreversible losses unless the conduct is enjoined, (ii) there is no adequate remedy in the form of compensatory damages, and (iii) there is a
substantial likelihood that the party will prevail on the merits, the parties agree to submit all disputes relating to the interpretation, enforcement, or breach of this Agreement to non-binding mediation before a mediator acceptable to both parties
in accordance with its Commercial Mediation Rules or such alternative mediator as the parties may approve in writing. 
  
 9.2 If the parties are unable to resolve their differences through mediation as provided in this Article 14 or if the matter is not subject to mediation under this
Article 14, either party may initiate a lawsuit to resolve the dispute. 
  
 ARTICLE 10 - CONFIDENTIALITY 
  
 10.1 Definition of
Confidential Information. It is contemplated that in the course of the performance of this Agreement each party may, from time to time, disclose proprietary and confidential information to the other (“Confidential Information”).
Confidential Information shall include all disclosures made hereunder or under previous confidentiality agreements between the Parties in writing and identified as being “Confidential,” or if disclosed orally, which are reduced to writing
within thirty (30) days of oral disclosure and clearly identified as being “Confidential.” FHCRC and LICENSEE agree that this Agreement shall supersede all previous confidentiality agreements between the parties and all disclosures made
under any previous confidentiality agreements shall be subject to the terms of this Section 10. 
  
 10.2 Nondisclosure of Confidential Information. Except to the extent expressly authorized by this Agreement or otherwise agreed to in writing, during the term of this Agreement and for a period of five (5)
years following the termination of this Agreement, each party shall take such 

  

 8 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 
reasonable measures to protect the secrecy of and avoid disclosure or use of such Confidential Information of the other party in order to prevent it from
falling into the public domain or the possession of any person other than those persons authorized under this Agreement to have any such information. Such measures shall include, but not be limited to, the highest degree of care the receiving party
takes to protect its own proprietary and confidential information of a similar nature, which shall be no less than reasonable care. Neither party shall disclose or permit disclosure of any Confidential Information of the other party to third parties
or to employees of the party receiving Confidential Information, other than directors, officers, employees, consultants and agents who are required to have the information in order to carry out the terms of this Agreement. Each party shall notify
the other in writing of any actual or suspected misuse, misappropriation or unauthorized disclosure of the other party’s Confidential Information that may come to such party’s attention. Not withstanding the foregoing, Confidential
Information from FHCRC shall include but not be limited to devices, cell lines, monoclonal antibodies, methods, processes, data regarding testing and experiments, drawings, documentation, patent applications and product development plans, is
FHCRC’s confidential, proprietary, trade secret information. 
  
 10.3
Exceptions. The following information shall not be considered Confidential Information: 
  

	 	(a)	information which was already known to the receiving party, other than under an obligation of confidentiality to the disclosing party, at the time of disclosure by the other party
as shown by the receiving parties written records; 

  

	 	(b)	information which was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving party; 

  

	 	(c)	information which becomes generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving
party in breach of this Agreement; 

  

	 	(d)	information which was disclosed to the receiving party, other than under an obligation of confidentiality, by a third party who had no obligation to the disclosing party not to
disclose such information; or 

  

	 	(e)	information which was developed independently without reference to Confidential Information received from the other party hereunder as evidenced by the receiving party’s own
written records. 

  
 10.4 Permitted Usage. Notwithstanding
the provisions of Section 10.1 above, the receiving party may use or disclose Confidential Information of the disclosing party in connection with the exercise of its rights hereunder (including commercialization and/or sublicensing) or the
fulfillment of its obligations and/or duties hereunder and in filing for, prosecuting or maintaining any proprietary rights, prosecuting or defending litigation, complying with applicable governmental regulations and/or submitting information to tax
or other governmental authorities; provided that if the receiving party is required by law to make any public disclosures of Confidential Information of the disclosing party, to the extent it may legally do so, it shall give 

  

 9 

 
reasonable advance notice to the disclosing party of such disclosure and shall use its reasonable efforts to secure confidential treatment of Confidential
Information prior to its disclosure (whether through protective orders or otherwise) ; and, provided, further, that to the extent that the receiving party is disclosing information to a third party for commercialization or sublicensing that the
third party has agreed to terms at least as restrictive as the terms of this Article 10 and may not further disclose the information to any third party and FHCRC has been provided with a copy of the agreement. 
  
 ARTICLE 11 - TERMINATION OF AGREEMENT 
  
 11.1 Termination on Payment Default. At FHCRC’s option, FHCRC may terminate this
Agreement effective thirty (30) days after giving written notice in the event LICENSEE fails to pay any royalties or other amounts owed under this Agreement when due. During the thirty (30) day period after written notice of payment default,
LICENSEE has the right to cure any payment default and prevent termination under this Section 11.1. 
  
 11.2 Termination on Other Defaults. This Agreement may be terminated by either party upon a material breach by the other party other than a payment default which is governed by Section 11.1, effective ninety
(90) days after giving written notice to the breaching party of such termination under this Section and specifying such breach, unless the breach is cured or shown to be non-existent within the ninety (90) day period, in which case the Agreement
will remain in effect. 
  
 11.3 Termination on Bankruptcy or Insolvency.
Subject to any provisions of the federal bankruptcy laws limiting rights of termination, FHCRC may terminate this Agreement if LICENSEE files for protection under federal bankruptcy laws, becomes insolvent, makes an assignment for the benefit of
creditors, appoints or suffers appointment of a receiver or trustee over its property, files a petition under any bankruptcy or insolvency act or has any such petition filed against it or files for dissolution. 
  
 11.4 Termination by LICENSEE. LICENSEE may terminate this Agreement in its entirety
for any reason or no reason with thirty (30) days written notice to FHCRC. 
  
 11.5 Effect of Termination. Upon termination of this Agreement, each party will turn over to the other party all Confidential Information of such other party and all documents or data storage media containing any such Confidential
Information and any and all copies thereof and will delete all such Confidential Information from its documents or data storage media. In addition, upon termination of this Agreement, LICENSEE shall return to FHCRC or destroy, at FHCRC’s option
and expense all of the LICENSED CELL LINE and all LICENSED MONOCLONAL ANTIBODY in possession of LICENSEE or any AFFILIATE sublicensee or other third party who has received the LICENSED CELL LINE or LICENSED MONOCLONAL ANTIBODY from LICENSEE provided
that LICENSEE shall be entitled to sell LICENSED PRODUCT as provided in Section 11.7 of this Agreement. Upon termination of this Agreement the Licenses shall terminate. Neither party shall be able to claim from the other party any damages or
compensation for loses or expenses resulting solely from termination of this Agreement as permitted under this Section 11. 
  

 10 

 11.6 Effect of Termination on Sublicensees. Any sublicenses granted by LICENSEE under this Agreement shall provide
for termination or assignment to FHCRC at FHCRC’s sole discretion, of LICENSEE’s interests therein upon termination of this Agreement for any reason. 
  

11.7 Sale of Products on Termination. In the event of any early termination of this Agreement in accordance with this Article 11, for a period of six (6) months
after termination LICENSEE shall have the right to sell all LICENSED PRODUCTS on hand at the time of such termination, provided that LICENSEE shall make all payments with respect thereto to FHCRC in accordance with this Agreement. 
  
 11.8 Final Report. Upon termination, a final report shall promptly be submitted in
accordance with the provisions of Section 5.4, together with any royalty payments and unreimbursed patent expenses due to FHCRC. 
  
 11.9 Survival of Rights and Duties. Rights and duties hereunder which by their terms or nature survive the termination or expiration of this Agreement shall so
survive such termination or expiration, including without limitation LICENSEE’s duties under Articles 5 through 11 and 15. 
  
 ARTICLE 12 - REPRESENTATIONS AND COVENANTS 
  
 12.1 LICENSEE Representations and Warranties. LICENSEE represents and warrants to FHCRC that it has obtained and will at all times during the Term hold and comply
with all licenses, permits and authorizations necessary to LICENSEE’s complete and timely performance of its obligations under this Agreement which are required under any applicable statutes, laws, ordinances, rules and regulations of the
United States as well as those of all applicable foreign governmental bodies, agencies and subdivisions, having, asserting or claiming jurisdiction over LICENSEE or LICENSEE’s performance of the terms of this Agreement. In particular, LICENSEE:

  
 (a) will be responsible for obtaining all necessary United
States Food and Drug Administration approvals and all approvals required by similar governmental bodies or agencies of all applicable foreign countries; and 
  
 (b) understands and acknowledges that the transfer of certain commodities and technical data is subject to United States laws and regulations controlling
the export of such commodities and technical data, including all Export Administration Regulations of the United States Department of Commerce. These laws and regulations, among other things, prohibit or require a license for the export of certain
types of technical data to certain specified countries. LICENSEE hereby agrees and gives written assurance that it will comply with all United States laws and regulations controlling the export of commodities and technical data, that it will be
solely responsible for any violation of such by LICENSEE or its AFFILIATES or sublicensees, and that it will defend and hold FHCRC harmless in the event of any legal action of any nature occasioned by such violation. 
  

 11 

 12.2 FHCRC Representations and Covenants. FHCRC warrants and represents to LICENSEE that: (i) it has and will
maintain the full right and authority to enter into this Agreement and grant the rights and licenses granted herein; (ii) it has not previously granted and will not grant any rights or licenses in conflict with the rights and licenses granted
herein; (iii) to its knowledge no action, suit or claim has been initiated or threatened with respect to the LICENSED MATERIALS that would call into question FHCRC’s right to enter into and perform its obligations under this Agreement;

  
 12.3 Disclaimer of Warranty. To Licensee, its AFFILIATES, its
sublicensees and customers or otherwise, express or implied, oral or written, arising by law, course of dealing, course of performance usage of trade or otherwise, with respect to the LICENSED CELL LINE, LICENSED MONOCLONAL ANTIBODY, LICENSED
PRODUCT, LICENSED TECHNICAL INFORMATION, including without limitation all warranties as to the condition, manufacture, sale, use, operation, design, quality, capacity, latent defects, compliance with any law, ordinance, regulation, rule, contract or
specification, “merchantability,” fitness for any particular purpose, and all other qualities and characteristics whatsoever. FHCRC neither assumes nor authorizes LICENSEE or any person to assume for FHCRC any liability in connection with
the manufacture, sale or use of any LICENSED PRODUCT. In no event shall FHCRC be liable for any consequential, incidental or special damages or expenses (including without limitation labor, transportation, loss of use, loss of profits and damage to
persons or property) even if FHCRC has been advised of the possibility thereof. 
  
 ARTICLE 13 - COMMERCIALLY REASONABLE EFFORTS 
  
 13.1 Reasonable Efforts. LICENSEE shall use reasonable effort to introduce the LICENSED PRODUCTS into the commercial market within five (5) years of the Effective Date, consistent with sound and reasonable business practices and
judgment, and thereafter endeavor to keep LICENSED PRODUCTS reasonably available to the public. 
  
 ARTICLE 14 - NOTICES 
  
 14.1
Notices. All communications, including payments, notices, demands or requests required or permitted to be given hereunder, shall be given in writing and shall be: 
  
 (a) personally delivered; 
  
 (b) sent by facsimile or other electronic means of transmitting written documents; or 
  
 (c) sent to the parties at their respective addresses indicated herein by registered or certified U.S. mail, return receipt
requested and postage prepaid, or by private overnight mail courier service. The respective addresses to be used for all such payments, notices, demands or requests are as follows: 
  

	If to FHCRC:	Fred Hutchinson Cancer Research Center 

	    	1100 Fairview Ave. N., C2M-027 

	    	Seattle, Washington 98109 

	 	Attention:	Rosalie Beer, 

  

 12 

	    	Senior Licensing Associate 

	 	Facsimile:	(206) 667-4732 

  

	With copies to:	Douglas J. Shaeffer, Esq. 

	    	Fred Hutchinson Cancer Research Center 

	    	1100 Fairview Ave. N., C2M-027 

	    	Seattle, Washington 98109 

	    	Facsimile: (206) 667-6590 

  

	If to LICENSEE:	Xcyte Therapies, Inc. 

	    	2203 Airport Way South, Suite 300 

	    	Seattle, WA 98134 

	 	Attention:	Business Development 

	 	Facsimile:	(206) 328-7316 

  

	With copies to:	Venture Law Group 

	    	4750 Carillon Point 

	    	Kirkland, Washington 98033-7355 

	    	Attn:    William W. Ericson 

	 	Facsimile:	(425) 739-8750 

  
 If personally delivered, such communication shall be deemed delivered upon actual receipt. If electronically transmitted pursuant to this section, such communication shall be deemed delivered when transmitted. If sent
by overnight courier pursuant to this section, such communication shall be deemed delivered within twenty-four hours of deposit with such courier. If sent by U.S. mail pursuant to this section, such communications shall be deemed delivered as of the
date of delivery indicated on the receipt issued by the relevant postal service, or, if the addressee fails or refuses to accept delivery, as of the date of such failure or refusal. Any party to this Agreement may change their address for the
purposes of this Agreement by giving notice in accordance with this Section. 
  
 ARTICLE 15 - MISCELLANEOUS 
  
 15.1
Governing Law. The rights and obligations of the parties under this Agreement shall be governed by and construed in accordance with the laws of the State of Washington. 
  
 15.2 Amendments. This Agreement may not be amended except by an instrument in writing signed by both parties. 
  
 15.3 Assignability. The Agreement shall be binding on the parties hereto and upon
their respective heirs, administrators, successors and assigns. This Agreement may not be assigned by LICENSEE or by operation of law without the prior written consent of FHCRC, which consent shall not be unreasonably withheld; except either party
may assign this Agreement, without such consent, to (i) an AFFILIATE of such party; or (ii) an entity that acquires all or substantially all of the business or assets of such party to which this Agreement pertains, whether by merger, 

  

 13 

 
reorganization, acquisition, sale or otherwise, and that agrees in writing to be strictly bound by the terms and conditions of this Agreement. 
  
 15.4 Non-Profit Status. LICENSEE acknowledges that FHCRC is a non-profit organization
qualifying for and holding the status of an exempt organization under Section 50l(c)(3) of the United States Internal Revenue Code. If the Internal Revenue Service determines, or a determination by FHCRC based on advice of legal or tax counsel is
reasonably made, that any part or all of this Agreement will jeopardize FHCRC’s Section 501(c)(3) status, the parties agree to meet and confer in good faith to amend this Agreement to the extent necessary to satisfy Internal Revenue Service
requirements for retention of FHCRC’s Section 50l(c)(3) status. If FHCRC and LICENSEE cannot agree within 30 days after commencing negotiations regarding the amendments to be made to this Agreement in order for FHCRC to retain its Section
501(c)(3) status, FHCRC may terminate this Agreement effective upon giving written notice to LICENSEE of termination under this Section 10. 
  
 15.5 Conflicts with Grants. LICENSEE understands and acknowledges that agreements between FHCRC and agencies of the United States Government funding FHCRC’s
programs may contain clauses granting patent and/or other rights to the agencies or the U.S. Government; LICENSEE agrees that the rights granted to it under this Agreement shall be subject to any rights of the agencies and the U.S. Government. If a
conflict arises, the provisions of any U.S. Government agency funding agreement and/or regulation shall prevail over any conflicting provisions of this Agreement and FHCRC will have no liability to LICENSEE as a result of such conflict. If such a
conflict arises or is reasonably anticipated, FHCRC will promptly give notice to LICENSEE of the nature of the conflict and copies of any correspondence relating thereto in accordance with Section 14.1. 
  
 15.6 Use of Name. Neither party shall use the name of the other party or reveal the
terms of this Agreement in any publicity or advertising without the prior written approval of the other party, except that (i) either party may use the text of a written statement approved in advance by both parties without further approval; (ii)
either party shall have the right to identify the other party and to disclose the terms of this Agreement as required by applicable securities laws or other applicable law or regulation; and (iii) either party may disclose that a licensing
relationship exists between the parties and may disclose the name of the other party in that context. 
  
 15.7 Written Notices. All letters, documents, or other materials of a written or physical nature, required by or relating to this Agreement shall be in English and sent to the party at the address given in
Article 14. 
  
 15.8 Independent Parties. The parties to this Agreement are
independent contractors and not agent of the other. This Agreement shall not constitute a partnership or joint venture, and neither party may be bound by the other to any contract, arrangement or understanding except as specifically stated herein.

  
 15.9 Enforceability. Should a court of competent jurisdiction later
consider any provision of this Agreement to be invalid, illegal, or unenforceable, it shall be considered severed from this Agreement. All other provisions, rights and obligations shall continue without regard to the 

  

 14 

 
severed provision, provided that the remaining provisions of this Agreement are in accord with the intention of the parties. 
  
 15.10 Actions. In the event any party to this Agreement commences any action or
proceeding, including an appeal of an action or proceeding, against the other, or otherwise retains an attorney, by reason of any breach or claimed breach of any provision of this Agreement, or to seek a judicial declaration of rights hereunder or
judicial or equitable relief, the prevailing party in such action or proceeding shall be entitled to recover its reasonable attorneys’ fees and costs. At the option of FHCRC, venue of any such legal or equitable action shall lie in Seattle,
Washington. LICENSEE hereby submits to the jurisdiction of the Federal District Court of Western Washington located in Seattle, Washington, and hereby agrees to accept service of process by certified mail, return receipt requested, effective upon
delivery to LICENSEE. 
  
 15.11 Force Majeure. LICENSEE and FHCRC shall not
be liable for loss, damage, detention or delay resulting from any cause whatsoever beyond its reasonable control or resulting from a force maj cure, including, without limitation, fire, flood, strike, lockout, civil or military authority,
insurrection, war, embargo, container or transportation shortage or delay of suppliers due to such causes, and delivery dates shall be extended to the extent of any delays resulting from the foregoing or similar causes. The party so affected shall
give prompt notice to the other party of such cause, and shall take whatever reasonable steps are necessary to relieve the effect of such cause as rapidly as reasonably possible. The party giving such notice shall thereupon be excused from such of
its obligations hereunder as it is thereby disabled from performing for so long as it is so disabled and for thirty (30) days thereafter, whichever is longer; provided, however, that such affected party commences and continues to take reasonable and
diligent actions to cure such cause. 
  

 15 

 IN WITNESS WHEREOF, the parties have executed this Agreement through duly authorized representatives as
of the date first above written. 
  

	
	 FRED HUTCHINSON CANCER RESEARCH CENTER

		
	 By
	 	 /s/ Douglas J. Shaeffer

	
	 Printed

	 Name Souglas J Shaeffer

	 Title, V.P. and General Counsel

	
	 XCYTE THERAPIES INC.

		
	 By
	 	 /s/ Ronald Jay Berenson

	
	 Printed

	 Name
	 	 Ronald Jay Berenson

		
	 Title
	 	 President & CEO

  

 16Services Agreement with Lonza Biologics PLC

 Exhibit 10.30 
  
 Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information
subject to the confidentiality request. Omissions are designated as [*****]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 
  
 AGREEMENT 
  
 For Services Relating to the [*] 
  
 Expressing [*] 
  
 Between 
  
 LONZA BIOLOGICS PLC 
  
 And 
  
 XCYTE THERAPIES, INC. 

 AGREEMENT 
  
 For Services Relating to the [*] 
  
 Expressing [*] 
  
 between 
  
 LONZA BIOLOGICS PLC 
  
 and 
  
 XCYTE THERAPIES, INC. 
  

 1 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 THIS AGREEMENT is made the 6 day of June, 2000 
  
 BETWEEN 
  

	1.	LONZA BIOLOGICS PLC, the registered office of which is at 228 Bath Road, Slough, Berkshire SL1 4DY, England (“LB”), and 

  

	2.	XCYTE THERAPIES, INC., of 1124 Columbia Street, Suite 130, Seattle, Washington 98104, USA, (“Customer”). 

  
 WHEREAS 
  

	A.	Customer is the proprietor of, or licensed to use, the [*] (designated at LB as [*]) expressing [*], and 

  

	B.	LB has the expertise in the development of process for and manufacture of similar products, and 

  

	C.	Customer wishes to contract with LB for services to develop a Process for and manufacture Product, and 

  

	D.	LB is prepared to perform such Services for Customer on the terms and conditions set out herein, and 

  

	E.	LB will where scientifically possible perform such Services in parallel with Services to produce [*] for Customer. 

  
 NOW THEREFORE it is agreed as follows: 
  

	1.	In this Agreement, its recitals and the schedules hereto, the words and phrases defined in Schedule 4 hereto and in the Standard Terms for Contract Services set out in Schedule 5
hereto shall have the meanings set out therein. 

  

	2.	Subject to the Standard Terms for Contract Services set out in Schedule 5 and any Special Terms, LB agrees to perform the Services and the Customer agrees to pay the Price together
with any additional costs and expenses that fall due hereunder. 

  

	3.       3.1	Any notice or other communication to be given under this Agreement shall be delivered personally or sent by facsimile transmission, or if facsimile transmission is not available, by
first class pre-paid post addressed as follows: 

  

	 	3.1.1	if to LB to: 

  
 Lonza Biologics plc 
 228 Bath Road

  

 2 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 Slough 
 Berkshire SL1 4DY 
  
 Facsimile:
01753 777001 
 For the attention of the Head of Legal Services 
  

	 	3.1.2	if to the Customer to: 

  
 Xcyte Therapies, Inc. 
 1124 Columbia Street

 Suite 130 
 Seattle

 Washington 98104 
  
 Facsimile: 206 262 0900 
 For the attention
of Director, Business Development 
  
 or to such other
destination as either party hereto may hereafter notify to the other in accordance with the provisions of this clause. 
  

	 	3.2	All such notices or other communications shall be deemed to have been served as follows: 

  

	 	3.2.1	if delivered personally, at the time of such delivery; 

  

	 	3.2.2	if sent by facsimile, upon receipt of the transmission confirmation slip showing completion of the transmission; 

  

	 	3.2.3	if sent by first class pre-paid post, ten (10) business days (Saturdays, Sundays and Bank or other public holidays excluded) after being placed in the post.

  
 AS WITNESS the hands of the duly authorised representatives of
the parties hereto the day and year first above written. 
  

	 Signed for and on behalf of
	 	 /s/ Edwin Davies

	 LONZA BIOLOGICS PLC
	 	 President                                     
            Title

		
	 Signed for and on behalf of
	 	 /s/ Ronald Jay Berenson

	 XCYTE THERAPIES, INC.
	 	 President & CEO
                                    Title

  

 3 

 SCHEDULE 1 
  

	[*]	

  

 4 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 SCHEDULE 2 
  

SERVICES 
  
 CONTENTS 
  

	[*]	

  

 5 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 SCHEDULE 3 
  

PRICE AND TERMS OF PAYMENT 
  
 1.0 Price 
  
 In consideration for LB carrying out the Services as detailed in Schedule 2 the Customer shall pay LB, as follows 
  

	 Stage

	 	 	  	Price (UK £ sterling)

	 1
	 	 [*]
	  	£105,000
	 2
	 	 [*]
	  	£64,000(1)
	 3
	 	 [*]
	  	£73,500
	 4
	 	 [*]
	  	£26,250
	 5
	 	 [*]
	  	£79,000
	 6
	 	 [*]
	  	£295,000(2)
	 7
	 	 [*]
	  	£17,000(3)
	 8
	 	 [*]
	  	£40,000(4)
	 9
	 	 [*]
	  	£30,000
	 10
	 	 [*]
	  	£57,750
	 11
	 	 [*]
	  	£12,500 per time point
	 12
	 	 [*]
	  	£50,000
	 13
	 	 [*]
	  	£7,000

  
 [*] 
  

	2.0	Payment 

  
 Payment by the Customer of the Price for each Stage shall be made against LB invoices on the following basis: 
  
 [*] 
  
  

 6 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 SCHEDULE 4 
  

[*] 
  

 7 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 SCHEDULE 5 
  

TERMS FOR CONTRACT SERVICES FOR [*] 
 FOR XCYTE THERAPIES, INC. 
  

	1.	Interpretation 

  

	 	1.1	In these Standard Terms, unless the context requires otherwise: 

  

	 	1.1.1	“Affiliate” means any Company, partnership or other entity which directly or indirectly controls, is controlled by or is under common control with the relevant party to
this Agreement. “Control” means the ownership of more than fifty per cent (50%) of the issued share capital or the legal power to direct or cause the direction of the general management and policies of the party in question.

  

	 	1.1.2	“Agreement” means any contract between LB and a Customer incorporating these Standard Terms. 

  

	 	1.1.3	“Cell Line” means the cell line, particulars of which are set out in Schedule 1. 

  

	 	1.1.4	“cGMP” means Good Manufacturing Practices and General Biologics Products Standards as promulgated under the US Federal Food Drug and Cosmetic Act at 21CFR (Chapters 210,
211, 600 and 610) and the Guide to Good Manufacturing Practices for Medicinal Products as promulgated under European Directive 91/356/EEC. LB’s operational quality standards are defined in internal GMP policy documents. Additional
product-specific development documentation and validation work may be required to support regulatory applications to conduct clinical trials or market a product. 

  

	 	1.1.5	“Customer” includes any person to whom a Proposal is issued by LB. 

  

	 	1.1.6	“Customer information” means all technical and other information not known to LB or in the public domain relating to the Cell Line, the Process and the Product, from time
to time supplied by the Customer to LB. 

  

	 	1.1.7	“Customer Materials” means the Materials supplied by Customer to LB (if any) and identified as such by Schedule 1 hereto. 

  

	 	1.1.8	“Customer Tests” means the tests to be carried out on the Product immediately following receipt of the Product by the Customer, particulars of which are set out in
Schedule 1. 

  

	 	1.1.9	“ex works” means LB has fulfilled its obligation to deliver when it has made the object of delivery available at its premises to the Customer or the Customer’s agent
(or to LB’s carrier if the provisions of Clause 5.1 of this Schedule 5 apply). For the avoidance of doubt, unless otherwise agreed in writing, LB is not responsible for loading the object of delivery on to the vehicle provided by the Customer
or the Customers agent (or to LB’s nominated carrier if Clause 5.1 of this Schedule 5 applies) or for delaying the object of delivery for export. 

  

 8 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

	 	1.1.10	“LB Know-How” means all technical and other information relating to the Process known to LB from time to time other than confidential Customer Information and information
in the public domain. 

  

	 	1.1.11	“Patent Rights” means all patents and patent applications of any kind throughout the world relating to the Process which from time to time LB is the owner of or is
entitled to use but not in any case any patent rights owned or controlled by Customer or its licensor/supplier. 

  

	 	1.1.12	“Price” means the price specified in Schedule 3 for the Services. 

  

	 	1.1.13	“Process” means the process for the production of the Product from the Cell Line, including any improvements thereto from time to time. 

  

	 	1.1.14	“Product” means all or any part of the product (including any sample thereof), particulars of which are set out in Schedule 1. 

  

	 	1.1.15	“Proposal” means any proposal or quotation issued by LB. 

  

	 	1.1.16	“Services” means all or any part of the services the subject of the Agreement or Proposal (including, without limitation, cell culture evaluation, purification evaluation,
master, working and extended cell bank creation, and sample and bulk production), particulars of which are set-out in Schedule 2. 

  

	 	1.1.17	“Special Term” means any term additional or supplemental to these Standard Terms from time to time agreed in writing between LB and the Customer. Particulars of any
Special Terms at the date of the Agreement are set out in Schedule 4. 

  

	 	1.1.18	“Specification” means the specification for Product, particulars of which are set out In Schedule 1. 

  

	 	1.1.19	“Terms of Payment” means the terms of payment specified in Schedule 3. 

  

	 	1.1.20	“Testing Laboratories” means any third party instructed by LB to carry out tests on the Cell Line or the Product. 

  

	 	1.2	Unless the context requires otherwise, words and phrases defined in any other part of the Agreement shall bear the same meanings in these Standard Terms, references to the singular
number include the plural and vice versa, references to Schedules are references to schedules to the Agreement, and references to Clauses are references to clauses of these Standard Terms. 

  

	 	1.3	In the event of a conflict between a Special Term and these Standard Terms, the Special Term shall prevail. 

  

	2.	Applicability of Standard Terms 

  

	 	2.1	 Unless agreed otherwise, these Standard Terms shall apply to every Proposal and Agreement, and to any services additional to the Services requested by a Customer.
LB shall not be bound by any terms which may be inconsistent with these Standard Terms and the Special Terms. No variation of or addition to these Standard Terms and the Special Terms or any other term of an Agreement shall be effective unless in
writing and signed for and on behalf of LB and Customer. For the avoidance of doubt, amendments to the draft Specification or Specification for Product shall be effective if reduced to writing and signed by the regulatory 

  

 9 

	 	 
representative of both Parties, which regulatory representative shall be nominated from time to time by the parties. 

  

	 	2.2	Unless previously withdrawn, a Proposal is open for acceptance within the period stated therein. Where no period is stated, the Proposal shall be open for acceptance within thirty
(30) days from the date it is issued unless withdrawn in the meantime. Any acceptance by a Customer of a Proposal shall not create a binding contract. 

  

	 	2.3	A binding contract shall only be created when LB has accepted in writing an offer placed by a Customer. 

  

	3.	Supply by Customer 

  

	 	3.1	Prior to or immediately following the date of the Agreement the Customer shall supply to LB the Customer Information, together with full details of any hazards relating to the Cell
Line and/or the Customer Materials, their storage and use. On review of this Customer Information, the Cell Line and/or the Customer Materials shall be provided to LB at LB’s request. Property in the Cell Line and/or the Customer Materials
supplied to LB shall remain vested in the Customer. 

  

	 	3.2	The Customer hereby grants LB [*]. LB hereby undertakes not to use the Cell Line, the Customer Materials or the Customer Information (or any part thereof) for any other
purpose. 

  

	 	3.3	LB shall: 

  

	 	3.3.1	at all times use all reasonable endeavours to keep the Cell Line and/or the Customer Materials secure and safe from loss and damage in such manner as LB stores its own material of
similar nature; 

  

	 	3.3.2	not part with possession of the Cell Line and/or the Customer Materials or the Product, save for the purpose of tests at the Testing Laboratories; and 

  

	 	3.3.3	procure that all Testing Laboratories are subject to obligations of confidence and restrictions to use and transfer substantially in the form of those obligations of confidence
imposed on LB under these Standard Terms. 

  

	 	3.4	The Customer warrants to LB that: 

  

	 	3.4.1	the Customer is and shall at all times throughout the duration of the Agreement remain entitled to supply the Cell Line, the Customer Materials and Customer Information to LB;

  

	 	3.4.2	to the best of the Customer’s knowledge and belief the use by LB of the Cell Line, the Customer Materials or and the Customer Information for the Services will not infringe any
rights (including, without limitation, any intellectual or industrial property rights) vested in any third party; and 

  

	 	3.4.3	the Customer will notify LB, in writing, immediately it knows or ought to know that it is no longer entitled to supply the Cell Line, the Customer Materials and/or the Customer
Information to LB or that the use by LB of the Cell Line, the Customer Materials or the Customer Information for the Services infringes or is alleged to infringe any rights (including, without limitation, any intellectual or industrial property
rights) vested in any third party. 

  

 10 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

	 	3.5	Provided that LB gives Customer prompt written notice and full particulars of any claim, tenders to Customer, full control of any defense or settlement and co-operates fully with
Customer, the Customer undertakes to indemnify and to maintain LB promptly indemnified against any loss, damage, costs and expenses of any nature (including court costs and legal fees on a full indemnity basis), whether direct or consequential, and
whether or not foreseeable or in the contemplation of LB or the Customer, that LB may suffer arising out of or incidental to any breach of the warranties given by the Customer under Clause 3.4 above or any claims alleging LB’s use of the Cell
Line, the Customer Materials or the Customer Information infringes any rights (including, without limitation, any intellectual or industrial property rights) vested in any third party (whether or not the Customer knows or ought to have known about
the same), however it is agreed that LB will retain its own independent legal counsel with settlement of any claim requiring LB’s prior written consent which shall not be unreasonably withheld. 

  

	 	3.6	The obligations of LB and the Customer under this Clause 3 shall survive the termination for whatever reason of the Agreement. 

  

	4.	Provision of the Services 

  

	 	4.1	LB shall diligently carry out the Services as provided in Schedule 2 and shall use all reasonable efforts to achieve the estimated timescales therefor. 

  

	 	4.2	Due to the unpredictable nature of the biological processes involved in the Services, the timescales set down for the performance of the Services (including without limitation the
dates for production and delivery of Product) and the quantities of Product for delivery set out in Schedule 2 are estimated only. 

  

	 	4.3	Provided that LB has complied with Section 4.1 the Customer shall not be entitled to cancel any unfulfilled part of the Services or to refuse to accept the Services on grounds of
late performance, late delivery or failure to produce the estimated quantities of Product for delivery. LB shall not be liable for any loss, damage, costs or expenses of any nature, whether direct or consequential, occasioned by:

  

	 	4.3.1	any delay in performance or delivery howsoever caused; or 

  

	 	4.3.2	any failure to produce the estimated quantities of Product for delivery. 

  

	 	4.4	LB shall comply with the regulatory requirements from time to applicable to the Services as set out in Schedule 2 hereto, including without limitation all relevant requirements of
current Good Manufacturing Practices under the policies and practices of the US FDA and European Regulatory Authorities and shall consider ICH and other relevant regulatory guidance documents whether or not set forth with precision in said Schedule
2. If the Customer requests LB to comply with any other regulatory or similar legislative requirements LB shall use all reasonable commercial endeavours to do so provided that: 

  

	 	4.4.1	the Customer shall be responsible for informing LB in writing of the precise foreign requirements which the Customer is requesting LB to observe; 

  

	 	4.4.2	such foreign requirements do not conflict with any mandatory requirements under the laws of England; 

  

 11 

	 	4.4.3	LB shall be under no obligation to ensure that such written information complies with the applicable requirements of any foreign jurisdiction; and 

  

	 	4.4.4	all costs and expenses incurred by LB in complying with such foreign requirements shall be charged to the Customer in addition to the Price. 

  

	 	4.5	Delivery of Product shall be ex-works LB’s premises (Incoterms 1990). Risk in and title to Product shall pass on delivery. Transportation of Product, whether or not under any
arrangements made by LB on behalf of the Customer, shall be made at the sole risk and expense of the Customer. 

  

	 	4.6	Unless otherwise agreed, LB shall package and label Product for delivery ex-works in accordance with its standard operating procedures. It shall be the responsibility of the
Customer to inform LB in writing in advance of any special packaging and labelling requirements for Product. All additional costs and expenses of whatever nature incurred by LB in complying with such special requirements shall be charged to the
Customer in addition to the Price. 

  

	5.	Transportation of Product and Customer Tests 

  

	 	5.1	If requested by the Customer, LB will (acting as agent of the Customer for such purpose) arrange the transportation of Product from LB’s premises to the destination indicated
by the Customer together with insurance cover for Product in transit at its invoiced value. All additional costs and expenses of whatever nature incurred by LB in arranging such transportation and insurance shall be charged to the Customer in
addition to the Price. 

  

	 	5.2	Where LB has made arrangements for the transportation of Product, the Customer shall diligently examine the Product as soon as practicable after receipt. Notice of all claims (time
being of the essence) arising out of: 

  

	 	5.2.1	damage to or total or partial loss of Product in transit shall be given in writing to LB and the carrier within three (3) working days of delivery; or 

  

	 	5.2.2	non-delivery shall be given in writing to LB within ten (10) days after the date of LB’s dispatch notice. 

  

	 	5.3	The Customer shall make damaged Product available for inspection and shall comply with the requirements of any insurance policy covering the Product notified by LB to the Customer.
LB shall offer the Customer all reasonable assistance (at the cost and expense of the Customer) in pursuing any claims arising out of the transportation of Product. 

  

	 	5.4	 Promptly following receipt of Product or any sample thereof, the Customer shall carry out the Customer Tests. PROVIDED ALWAYS the Specification for such Product is
not stated to be in draft form, if the Customer Tests show that the Product fails to meet Specification, the Customer shall give LB written notice thereof within forty-five (45) days from the date of delivery of the Product ex-works and shall return
such Product to LB’s premises for further testing. In the absence of such written notice Product shall be deemed to have been accepted by the Customer as meeting Specification. If LB is satisfied that Product returned to LB fails to meet
Specification and that such failure is not due (in whole or in part) to acts or omissions of the Customer or any third party after delivery of such Product ex-works, LB shall at Customer’s discretion refund that part of the Price 

  

 12 

	 	 
that relates to the production of such Product or replace such Product at its own cost and expense. In the event Customer requires LB to replace such
Product, LB shall be entitled to have regard to its commercial commitments to third parties in the timing of such replacement and will consider Customer’s requirements in as fair and equal manner as it considers other third party customer
requirements, Customer acknowledges that there may, therefore, be a delay in the timing of the replacement of such Product. 

  
 FOR THE AVOIDANCE OF DOUBT, WHERE THE SPECIFICATION IS STATED TO BE IN DRAFT FORM LB SHALL BE OBLIGED ONLY TO USE ITS REASONABLE ENDEAVOURS TO PRODUCE
PRODUCT THAT MEETS SPECIFICATION. 
  

	 	5.5	If there is any dispute concerning whether Product returned to LB, fails to meet Specification or whether such failure is due (in whole or in part) to acts or omissions of the
Customer or any third party after delivery of such Product ex-works, such dispute shall be referred for decision to an independent expert (acting as an expert and not as an arbitrator) to be appointed by agreement between LB and the Customer or, in
the absence of agreement by the President for the time being of the Association of the British Pharmaceutical Industry. The costs of such independent expert shall be borne equally between LB and the Customer. The decision of such independent expert
shall be in writing and, save for manifest error on the face of the decision, shall be binding on both LB and the Customer. 

  

	 	5.6	The provisions of Clauses 5.4 and 5.5 shall be the sole remedy available to the Customer in respect of Product that fails to meet Specification. 

  

	6.	Price and Terms of Payment 

  

	 	6.1	The Customer shall pay the Price in accordance with the Terms of Payment. 

  

	 	6.2	Unless otherwise indicated in writing by LB. all prices and charges are exclusive of Value Added Tax or of any other applicable taxes, levies, imposts, duties and fees of whatever
nature imposed by or under the authority of any government or public authority, which shall be paid by the Customer (other than taxes on LB’s income). All Invoices are strictly net and payment must be made within thirty (30) days of date of
invoice. Payment shall be made without deduction, deferment, set-off, lien or counterclaim of any nature. 

  

	 	6.3	In default of payment on due date: 

  

	 	6.3.1	interest shall accrue on any amount overdue at the rate of [*] above the base lending rate from time to time of HSBC Bank plc, interest to accrue on a day to day basis both
before and after judgement; and 

  

	 	6.3.2	LB shall, at its sole discretion, and without prejudice to any other of its accrued rights, be entitled to suspend the provision of the Services or to treat the Agreement as
repudiated by notice in writing to the Customer exercised at any time thereafter. 

  

	7.	Warranty and Limitation of Liability 

  

	 	7.1	LB warrants that: 

  

	 	7.1.1	the Services shall be performed in accordance with Clause 4.1; and 

  

 13 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

	 	7.1.2	the Product shall meet Specification on delivery, save where the Specification is stated to be in draft form when LB shall be obliged only to use its reasonable endeavours to
produce Product that meets Specification. 

  

	 	7.2	Clause 7.1 is in lieu of all conditions, warranties and statements in respect of the Services and/or the Product whether expressed or implied by statute, custom of the trade or
otherwise (including but without limitation any such condition, warranty or statement relating to the description or quality of the Product, its fitness for a particular purpose or use under any conditions whether or not known to LB) and any such
condition, warranty or statement is hereby excluded. 

  

	 	7.3	Without prejudice to the terms of Clauses 5.6, 7.1. 7.2, 7.4 and 7.6, the liability of LB for any loss or damage suffered by the Customer as a direct result of any breach of the
Agreement or of any other liability of LB (including misrepresentation and negligence or third party claim brought against Customer relating solely to LB know-how) in respect of the Services (including without limitation the production and/or supply
of the Product) shall be limited to the payment by LB of damages which shall not exceed [*]. 

  

	 	7.4	Subject to Clause 7.6, LB shall not be liable for the following loss or damage howsoever caused (even if foreseeable or in the contemplation of LB or the Customer):

  

	 	7.4.1	loss of profits, business or revenue whether suffered by the Customer or any other person; or 

  

	 	7.4.2	special, indirect or consequential loss, whether suffered by the Customer or any other person; and 

  

	 	7.4.3	any loss arising from any claim made against the Customer by any other person. 

  

	 	7.5	Provided that LB gives Customer prompt written notice and full particulars of any claim, tenders to Customer, full control of any defense or settlement, and co-operate fully with
Customer, the Customer shall indemnify and maintain LB promptly indemnified against all claims, actions, costs, expenses of any nature (including court costs and legal fees on a full indemnity basis) or other liabilities whatsoever in respect of the
following, it been agreed, however that LB will retain its own independent legal counsel with settlement of any claim requiring LB’s prior written consent which will not be unreasonably withheld: 

  

	 	7.5.1	any liability under the Consumer Protection Act 1987, unless such liability is caused by the negligent act or omission of LB in the production and/or supply of the Product; and

  

	 	7.5.2	any product liability (other than that referred to in Clause 7.5.1) in respect of Product, unless such liability is caused by the negligent act or omission of LB in the production
and/or supply of Product; and 

  

	 	7.5.3	any negligent or willful act or omission of the Customer in relation to the use, processing, storage or sale of the Product. 

  

	 	7.6	Nothing contained in these Standard Terms shall purport to exclude or restrict any liability for death or personal injury resulting directly from negligence by LB in

  
  

 14 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

	 	 
carrying out the Services or any liability for breach of the implied undertakings of LB as to title. 

  

	 	7.7	The obligations of LB and the Customer under this Clause 7 shall survive the termination for whatever reason of the Agreement. 

  

	8.	Customer Information, LB Know-How and Patent Rights 

  

	 	8.1	The Customer acknowledges that LB Know-How and LB acknowledges that Customer Information with which it is supplied by the other pursuant to the Agreement is supplied, subject to
Clause 8.4, in circumstances imparting an obligation of confidence and each agrees to keep such LB Know-How or such Customer Information secret and confidential and to respect the other’s proprietary rights therein and not at any time for any
reason whatsoever to disclose or permit such LB Know-How or such Customer Information to be disclosed to any third party save as expressly provided herein. 

  

	 	8.2	The Customer and LB shall each procure that all their respective employees, consultants and contractors having access to confidential LB Know-How or confidential Customer
Information shall be subject to the same obligations of confidence as the principals pursuant to Clause 8.1 and shall enter into secrecy agreements in support of such obligations. Insofar as this is not reasonably practicable, the principals shall
take all reasonable steps to ensure that any such employees, consultants and contractors are made aware of such obligations. 

  

	 	8.3	LB and the Customer each undertake not to disclose or permit to be disclosed to any third party, or otherwise make use of or permit to be made use of, any trade secrets or
confidential information relating to the technology, business affairs or finances of the other, any subsidiary, holding company or subsidiary or any such holding company of the other, or of any suppliers, agents, distributors, licensees or other
customers of the other which comes into its possession under this Agreement. 

  

	 	8.4	The obligations of confidence referred to in this Clause 8 shall not extend to any information which: 

  

	 	8.4.1	is or becomes generally available to the public otherwise than by reason of a breach by the recipient party of the provisions of this Clause 8; 

  

	 	8.4.2	is known to the recipient party and is at its free disposal prior to its receipt from the other; 

  

	 	8.4.3	is subsequently disclosed to the recipient party without being made subject to an obligation of confidence by a third party; 

  

	 	8.4.4	LB or the Customer may be required to disclose under any statutory, regulatory or similar legislative requirement, subject to the imposition of obligations of secrecy wherever
possible in that relation; or 

  

	 	8.4.5	is developed by any servant or agent of the recipient party without access to or use or knowledge of the information by the disclosing party. 

  

	 	8.5	The Customer acknowledges that: 

  

	 	8.5.1	LB Know-How and the Patent Rights are vested in LB or LB is otherwise entitled thereto; and 

  

 15 

	 	8.5.2	the Customer shall not at any time have any right, title, license or interest in or to LB Know-How, the Patent Rights or any other intellectual property rights relating to the
Process which are vested in LB or to which LB is otherwise entitled. 

  

	 	8.6	LB acknowledges that: 

  

	 	8.6.1	Customer has undertaken that the Customer Information is vested in the Customer or the Customer is otherwise entitled thereto; and 

  

	 	8.6.2	save as provided herein LB shall not at any time have any right, title, license or interest in or to the Customer information or any other Intellectual Property rights vested in
Customer or to which the Customer is entitled. 

  

	 	8.7	The obligations of LB and the Customer under this Clause 8 shall survive the termination for whatever reason of the Agreement. 

  

	9.	Termination 

  

	 	9.1	If it becomes apparent to either LB or the Customer at any stage in the provision of the Services that it will not be possible to complete the Services for scientific or technical
reasons, a sixty (60) day period shall be allowed for discussion to resolve such problems. If such problems are not resolved within such period, LB and the Customer shall each have the right to terminate the Agreement forthwith by notice in writing.
In the event of such termination, the Customer shall pay to LB a termination sum calculated by reference to all the Services performed by LB prior to such termination (including a pro rata proportion of the Price for any stage of the Services which
is in process at the date of termination) and all expenses reasonably incurred by LB in giving effect to such termination, including the costs of terminating any commitments entered into under the Agreement, such termination sum not to exceed the
balance of the Price for the remaining services not yet commenced, LB will engage in good faith efforts to offer to other third party customers those development resources or manufacturing slots which become available due to termination by Customer
of this Agreement, and Customer will not be required to pay for that portion of the Services and related expenses that LB is able to charge to such other customers. 

  

	 	9.2	Customer shall be entitled to terminate this Agreement at any time for any reason by sixty (60) days’ notice to LB in writing. In the event of Customer serving notice to
terminate this Agreement which notice is expressed to be given pursuant to this Clause 9.2, Customer shall: 

  

	 	9.2.1	pay LB a termination sum calculated in accordance with the principles of Clause 9.1 above, and 

  

	 	9.2.2	 In the event notice to terminate this Agreement pursuant to this Clause 9.2 is issued to LB within six (6) months of LB’s then estimated start date for any
stage of the Services which includes cGMP fermentation activities, Customer shall pay LB a sum (to the extent not already payable as noted above in accordance with the principles of Clause 9.1) equal to not less than ten percent (10%) nor more than
eighty-five percent (85%) of the full Price of that stage, or those stages, in question, as provided in Clause 9.2.3 

  

 16 

	 	 
below. Such payment shall fall due to LB on or before the date of termination of the Services. For the avoidance of doubt activities relating to cGMP
fermentation shall be deemed to commence with the date of removal of the vial of cells for the performance of the fermentation from frozen storage. 

  

	 	9.2.3	In the event of Customer serving notice to terminate this Agreement in the circumstances described in Clause 9.2.2, LB shall use reasonable endeavours to substitute a requirement
for the manufacturing slot which becomes available due to Customer of the Agreement. If LB finds such an alternative third party selling the manufacturing slot, which third party requirement is not for business (i.e. LB shall not be required to
reschedule parties), the fee payable by Customer under Clause 10% of the price for the manufacturing slot originally amount, if any, by which the fees to be paid for such customer is less than 85% of the price under this originally reserved for
Customer. If LB is substitute a third party requirement for the such manner, Customer shall be liable to of the price under this Agreement third party termination by and is successful in previously contracted existing commitments to third parties),
the fee payable by Customer under Clause 9.2.2 shall equal the greater of (a) reserved for Customer and (b) the manufacturing slot by such other Agreement for the manufacturing slot unable, by using reasonable endeavours, to manufacturing slot
reserved for Customer in pay LB under Clause 9.2.2 a sum equal to 85% for the manufacturing slot. 

  

	 	9.3	LB and the Customer may each terminate the Agreement forthwith by notice in writing to the other upon the occurrence of any of the following events: 

  

	 	9.3.1	if the other commits a breach of the Agreement which (in the case of a breach capable of remedy) is not remedied within thirty (30) days of the receipt by the other of notice
identifying the breach and requiring its remedy; or 

  

	 	9.3.2	if the other ceases for any reason to carry on business or compounds with or convenes a meeting of its creditors or has a receiver or manager appointed in respect of all or any part
of its assets or is the subject of an application for an administration order or of any proposal for a voluntary arrangement or enters into liquidation (whether compulsorily or voluntarily) or undergoes any analogous act or proceedings under foreign
law. 

  

	 	9.4	Upon the termination of the Agreement for whatever reason: 

  

	 	9.4.1	LB shall promptly return all Customer Information to the Customer and shall dispose of or return to the Customer the Customer Materials (and where supplied by Customer the Cell
Line) and any materials therefrom, as directed by the Customer; 

  

	 	9.4.2	the Customer shall promptly return to LB all LB Know-How it has received from LB; 

  

 17 

	 	9.4.3	the Customer shall not thereafter use or exploit the Patent Rights or the LB Know-How in any way whatsoever; 

  

	 	9.4.4	LB may thereafter use or exploit the Patent Rights or the LB Know-How in any way whatsoever without restriction; and 

  

	 	9.4.5	LB and the Customer shall do all such acts and things and shall sign and execute all such deeds and documents as the other may reasonably require to evidence compliance with this
Clause 9.4. 

  

	 	9.5	Termination of the Agreement for whatever reason shall not affect the accrued rights of either LB or the Customer arising under or out of this Agreement and all provisions which are
expressed to survive the Agreement shall remain in full force and effect. 

  

	10.	Force Majeure 

  

	 	10.1	If LB is prevented or delayed in the performance of any of its obligations under the Agreement by Force Majeure and shall give written notice thereof to the Customer specifying the
matters constituting Force Majeure together with such evidence as LB reasonably can give and specifying the period for which it is estimated that such prevention or delay will continue, LB shall be excused from the performance or the punctual
performance of such obligations as the case may be from the date of such notice for so long as such cause of prevention or delay shall continue. 

  

	 	10.2	The expression “Force Majeure” shall be deemed to include any cause affecting the performance by LB of the Agreement arising from or attributable to acts, events, acts of
God, omissions or accidents beyond the reasonable control of LB. 

  

	11.	Governing Law, Jurisdiction and Enforceability 

  

	 	11.1	The construction, validity and performance of the Agreement shall be governed by the laws of England, to the jurisdiction of whose courts LB and the Customer submit.

  

	 	11.2	No failure or delay on the part of either LB or the Customer to exercise or enforce any rights conferred on it by the Agreement shall be construed or operate as a waiver thereof nor
shall any single or partial exercise of any right, power or privilege or further exercise thereof operate so as to bar the exercise or enforcement thereof at any time or times thereafter. 

  

	 	11.3	The illegality or invalidity of any provision (or any part thereof) of the Agreement or these Standard Terms shall not affect the legality, validity or enforceability of the
remainder of its provisions or the other parts of such provision as the case may be. 

  

	12.	Miscellaneous 

  

	 	12.1	 Neither party shall be entitled to assign, transfer, charge or in any way make over the benefit and/or the burden of this Agreement without the prior written
consent of the other which consent shall not be unreasonably withheld or delayed, save that either LB or the Customer shall respectively be entitled without the prior written consent of the other to assign, transfer, charge, sub-contract, deal with
or in any other manner make over the benefit and/or burden of this Agreement to an 

  

 18 

	 	 
Affiliate or to any 50/50 joint venture company of which either party is the beneficial owner or fifty per cent (50%) of the issued share capital thereof or
to any company with which either party may merge or to any company to which that party may transfer its assets and undertakings. 

  

	 	12.2	The text of any press release or other communication to be published by or in the media concerning the subject matter of the Agreement shall require the prior written approval of LB
and the Customer. 

  

	 	12.3	The Agreement embodies the entire understanding of LB and the Customer and there are no promises, terms, conditions or obligations, oral or written, expressed on implied, other than
those contained in the Agreement. The terms of the Agreement shall supersede all previous agreements (if any) which may exist or have existed between LB and the Customer relating to the Services. 

  

 19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}]]